Tilray Brands (TLRY) Long-Term Deferred Tax (2018 - 2025)
Tilray Brands (TLRY) posted Long-Term Deferred Tax of $42.3 million for Q2 2025, down 62.74% on a QoQ basis from $113.6 million in Q2 2024, and down 62.74% year-over-year from $113.6 million in Q2 2024.
Tilray Brands (TLRY) Long-Term Deferred Tax (2018 - 2025) Analysis & Trends
Tilray Brands' Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $42.3 million for Q2 2025.
- Quarterly Long-Term Deferred Tax fell 62.74% year-over-year to $42.3 million in Q2 2025, while the trailing twelve-month figure through May 2025 was $42.3 million (down 62.74% YoY) and the FY2025 annual result came in at $42.3 million, down 62.74% from the prior year.
- Long-Term Deferred Tax was $42.3 million for Q2 2025 at Tilray Brands, down from $113.6 million in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $113.6 million in Q2 2024 and bottomed at $42.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2025 | 42.34 Mn |
| May 31, 2024 | 113.63 Mn |
| Dec 31, 2018 | 27,000.00 |